Setmelanotide
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Rhythm · Phase 2 · Completed · Enrollment 40
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Setmelanotide 0.5 mg | Prader-Willi Syndrome | 0.5 mg | n/r | n/r | n/r |
| Setmelanotide 1.5 mg | Prader-Willi Syndrome | 1.5 mg | n/r | n/r | n/r |
| Setmelanotide 2.5 mg | Prader-Willi Syndrome | 2.5 mg | n/r | n/r | n/r |
| Placebo | Prader-Willi Syndrome | n/r | n/r | n/r | n/r |